相关实验视频

Updated: Sep 17, 2025

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

基于质谱的新型免疫不动化试验,使结构-活性关系发展成为可能乳胺结合蛋白 (EBP) 抑制剂

Ronghai Cheng¹, Paramasivam Murugan², Meiyi Zhang³

¹Bioassays & High-throughput Screens, Synthetic Medicine Design, Biogen, Cambridge, Massachusetts 02142, United States.

Journal of the American Society for Mass Spectrometry

|July 3, 2025

概括

一个新的试验增强了Emopamil结合蛋白 (EBP) 活性,用于药物发现. 这种方法支持开发EBP抑制剂用于神经退行性疾病,如多发性硬化症,通过提高试验吞吐量和可重复性.

科学领域:

生物化学生物化学
神经科学是一个神经科学.
药物发现药物发现药物发现

背景情况:

埃莫帕米尔结合蛋白 (EBP) 在胆固醇生物合成中至关重要,转化醇异构体.
抑制EBP是神经退行性疾病的治疗点,包括多发性硬化症,通过促进寡细胞分化.
开发EBP的小分子抑制剂是具有挑战性的,因为在净化过程中酶产量低和活性丧失.

研究的目的:

开发一种可靠的功能性试验,用于对埃莫帕米尔结合蛋白 (EBP) 抑制剂的结构-活性关系 (SAR) 研究.
克服EBP生产和测试吞吐量方面的挑战,以实现高效的药物发现.

主要方法:

活性EBP的免疫动员,在Expi293F细胞中过度表达.
免疫动员EBP与液体染色学-大气压化学电离多重反应监测质谱学 (LC-APCI MRM MS) 的合.
自动醇提取和高速LC自动采样器,以提高吞吐量.

主要成果:

与纯化重组EBP (recEBP) 相比,该试验在纳米分子度下显著增强了EBP酶活性.
取得了优异的测试可重现性和稳定性,适合SAR开发.
在多个运行过程中证明了高质量的度-反应曲线 (CRC) 和一致的抑制功率 (pIC50) 值.

结论:

开发的功能性试验是EBP抑制剂SAR研究的强大和高通量方法.
这种测定有助于EBP抑制剂作为神经退行性疾病的潜在治疗方法的发展.
该方法提供了增强的EBP酶活性和可靠的药物发现功效测量.

更多相关视频

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B

Published on: January 19, 2022

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

An HS-MRM Assay for the Quantification of Host-cell Proteins in Protein Biopharmaceuticals by Liquid Chromatography Ion Mobility QTOF Mass Spectrometry

Published on: April 17, 2018

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

The Equilibrium Binding Constant and Binding Strength

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium: